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Minichromosome maintenance proteins (MCM) have recently emerged as novel proliferation markers with prognostic implications in
several tumour types. This is the first study investigating MCM-2 and MCM-5 immunohistochemical expression in a series of ovarian
adenocarcinomas and low malignant potential (LMP) tumours aiming to determine possible associations with clinicopathological
parameters, the conventional proliferation index Ki-67, cell cycle regulators (p53, p27
Kip1, p21
WAF1 and pRb) and patients’ outcome.
Immunohistochemistry was applied in a series of 43 cases of ovarian LMP tumours and 85 cases of adenocarcinomas. Survival analysis
was restricted to adenocarcinomas. The median MCM-2 and MCM-5 labelling indices (LIs) were significantly higher in
adenocarcinomas compared to LMP tumours (Po0.0001 for both associations). In adenocarcinomas, the levels of MCM-2 and
MCM-5 increased significantly with advancing tumour stage (P¼0.0052 and P¼0.0180, respectively), whereas both MCM-2 and
MCM-5 increased significantly with increasing tumour grade (P¼0.0002 and P¼0.0006, respectively) and the presence of bulky
residual disease (Po0.0001 in both relationships). A strong positive correlation was established between MCM-2 or MCM-5
expression level and Ki-67 LI (Po0.0001) as well as p53 protein (P¼0.0038 and P¼0.0500, respectively). Moreover, MCM-2 LI was
inversely correlated with p27
Kip 1 LI (P¼0.0068). Finally, both MCM-2 and MCM-5 were associated significantly with adverse
patients’ outcome in both univariate (X20 vs 420%, P¼0.0011 and X25 vs o25%, P¼0.0100, respectively) and multivariate
(P¼0.0001 and 0.0090, respectively) analysis. An adequately powered independent group of 45 patients was used in order to
validate our results in univariate survival analysis. In this group, MCM-2 and MCM-5 expression retained their prognostic significance
(Po0.0001 in both relationships). In conclusion, MCM-2 and MCM-5 proteins appear to be promising as prognostic markers in
patients with ovarian adenocarcinomas.
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The most consistently reported significant prognostic indicators
for human ovarian cancer are disease stage, tumour grade,
histologic type and extent of surgical cytoreduction (Ozols,
2002). However, there remains a significant degree of biologic
heterogeneity even within the same prognostic subgroups,
hampering the accurate prediction of clinical behaviour in
individual cases (Ozols, 2002). Thus, gaining insight into the
molecular determinants of the biologic behaviour of ovarian
cancer is imperative to identify groups of patients with a
particularly poor prognosis.
The rapidly advancing understanding of mammalian DNA
replication has given rise to a new generation of proliferation
markers. Recently, positive and negative regulators of DNA
replication have emerged as novel tumour biomarkers that may
potentially be used for screening, estimation of prognosis and
assessment of treatment response for a range of tumour types
(Tachibana et al, 2005). Minichromosome maintenance (MCM)
proteins drive the formation of prereplicative complexes (PRCs),
which is the first key event during G1 phase (Tye, 1999). In all
eukaryotic cells, initiation of DNA synthesis is a complex multistep
process tightly coupled to progression through the cell cycle (Ritzi
and Knippers, 2000). In the first step, during the G1 phase key
replication initiation factors, including the origin recognition
complex, the Cdc6 protein and the MCM proteins 2–7 are
recruited into PRCs at future replication origins, establishing the
competence of particular chromatin regions for initiation of DNA
synthesis (Tye, 1999; Labib and Diffley, 2001; Lei and Tye, 2001;
Yu et al, 2004b). The MCMs are highly conserved proteins
presumed to act as an enzymatically active helicase (Labib and
Diffley, 2001). In the second step, unwinding of replication origins
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sand establishment of bi-directional replication forks take place to
control entry into the S phase (Labib and Diffley, 2001). As the
DNA is replicated, MCM proteins gradually dissociate from
chromatin, ensuring that each region of DNA is replicated only
once during a single cell cycle, because replicated DNA lacks
functional PRCs (Labib and Diffley, 2001). As the cells leave the
cell cycle to enter into the quiescent, differentiated and senescent
states, the Cdc6 and MCM components of the replication initiation
pathway are downregulated (Stoeber et al, 2001).
Recently, several groups have reported that MCM immuno-
reactivity is a specific and accurate marker for proliferating cells
(Todorov et al, 1998; Freeman et al, 1999; Heidebrecht et al, 2001;
Kodani et al, 2001; Stoeber et al, 2001). Other advantages of MCMs
are that they do not detect cells undergoing DNA repair and they
are not downregulated in proliferating cells by nutritional
deprivation, which may be operating regionally in solid tumours
(Osaki et al, 2002). Also, their function has been well characterised
in several in vitro systems (Tye, 1999) representing a point of
convergence for numerous signalling pathways involved in cell
growth (Stoeber et al, 2001) and their levels change little during the
cell cycle, decreasing markedly in cells with a lower proliferation
rate (Todorov et al, 1994).
To the best of our knowledge, there is only one previous study
assessing MCMs in ovarian neoplasia (Scott et al, 2004). However,
this study has focused solely on serous neoplasms and has
investigated only MCM-2 protein expression. More importantly,
nothing is known about the prognostic utility of MCM proteins in
ovarian cancer. The aim of the present study was to investigate the
immunohistochemical expression of MCM-2 and MCM-5 proteins
in a series of low malignant potential (LMP) tumours and ovarian
carcinomas of all histologic types and to determine for the first
time the possible associations with clinicopathologic parameters,
the conventional proliferation index Ki-67, other cell cycle
regulators (p53, p27
Kip1, p21
WAF1 and pRb) and patients’ outcome.
MATERIALS AND METHODS
Study populations
Patient population This is a retrospective study of 128 con-
secutive cases of epithelial ovarian tumours of LMP and
adenocarcinomas, diagnosed and treated at Alexandra General
Hospital and Iasso Gynaecologic Institute of Athens between 1989
and 1999, for whom paraffin-embedded tissue and clinical
information were available. Eighty-five specimens were defined
as ovarian adenocarcinomas, whereas 43 specimens fulfilled the
criteria of LMP tumours (Scully and Sobin, 1987; Russel, 1994).
Histologic classification of tumours was carried out according to
the World Health Organization System (Scully and Sobin, 1987).
Poorly differentiated adenocarcinoma was the diagnosis for those
carcinomas that did not show evident cellular differentiation.
Adenocarcinomas were graded as well, moderately and poorly
differentiated (Scully and Sobin, 1987) and patients were assigned
a clinical stage according to the International Federation of
Gynecology and Obstetrics (Cancer Committee of FIGO, 1986)
standards. Surgical and pathologic findings and postoperative
abdomino-pelvic computerised tomography (CT) scans were used
to determine the FIGO stage for the ovarian adenocarcinomas and
the residual disease after the initial surgery. Persistence of tumour
masses of o2cm was defined as minimal residual disease, whereas
the presence of masses of 42cm in diameter was defined as bulk
residual disease (Anttila et al, 1999; Sengupta et al, 2000).
All patients with carcinomas had undergone total abdominal
hysterectomy with bilateral salpingo-oophorectomy followed by
chemotherapy. None had received preoperative chemotherapy or
radiotherapy. The clinicopathologic characteristics of these
patients are summarised in Table 1. Follow-up information was
available in 79 patients. By the time this study was undertaken, 26
patients had died of their disease after a median survival of 15.6
(range 1–60) months. The median follow-up for the remaining 53
patients was 43 (range 11.7–126) months.
Validation group
An independent set of patients with ovarian adenocarcinoma was
used to validate our results of univariate survival analysis and test
the validity of the chosen cutoff values for the expression of MCM-2
and MCM-5 proteins. The results of univariate survival analysis for
MCM-2 and MCM-5 expression in the population group were used
to calculate the required number of patients in the validation
group for an adequately powered analysis (90%) (Lachin and
Foulkes, 1986). Lachin (1981) have showed that the equation
relating total sample size and power for a univariate survival
analysis test in simple sets is given by the following equation:
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where le, lc the respective hazard ratios in the two groups,
Qi¼ni/N, l¼QclcþQele and Za, Zb the standard normal
derivatives at levels a and b, respectively.
Given that our study implies non-uniform patients’ entry and
consequently follow-up, this type can be transformed when we
Table 1 Clinical data of patients in the study population with ovarian
LMP tumours and adenocarcinomas
Age (years)
Median (range) 51.6 (20–86)
Histological type
LMP tumours
Serous 29 (67.4%)
Mucinous 14 (32.6%)
Adenocarcinomas
Serous 34 (40%)
Mucinous 10 (11.76%)
Endometrioid 16 (18.82%)
Clear cell 18 (21.17%)
Poorly differentiated 3 (3.5%)
Not specified 4 (4.7%)
Histologic grade
1 13 (15.3%)
2 240 (47.1%)
3 32 (37.6%)
FIGO stage
I 25 (29.5%)
II 3 (3.5%)
III 42 (49.4%)
IV 11 (12.9%)
Not specified 4 (4.7%)
Primary residual tumour
No 39 (45.9%)
Yes 46 (54.1%)
Adjuvant chemotherapy
Platinum-containing 64 (75.3%)
Non platinum-containing 21 (24.7%)
Clinical outcome
Died of ovarian cancer 26 (30.6%)
Alive 53 (62.4%)
Not specified 6 (0.7%)
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ssuppose the following exponential entry distribution (Lachin and
Foulkes, 1986).
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Sample size and power can be calculated by substituting this type
into the above.
The validation group consisted of 45 patients with primary
ovarian adenocarcinoma, diagnosed and treated at Alexandra
General Hospital between 1994 and 2004, for whom paraffin-
embedded tissue was available. Follow-up period ranged from 1.3
to 124 months (median: 23.96 months). During this period, 16
disease-specific deaths were recorded, whereas the median (range)
follow-up for the remaining 29 cases was 28.5 (9–124) months.
The clinicopathologic data of the validation group are summarised
in Table 2.
Processing of specimens and immunohistochemistry
Tissues were fixed immediately after removal in 10% buffered
formalin and processed to paraffin wax. Four micrometres serial
sections were cut from each specimen on Superfrost plus glass
slides and left to dry overnight at 371C. In addition, from our
previous investigations (Korkolopoulou et al, 2002; Konstantinidou
et al, 2003; Vassilopoulos et al, 2003), results regarding the
expression of p53, p27
Kip1, pRb, p21
WAF1 and Ki-67 were available
in all cases. The following monoclonal antibodies were used: (1)
MCA 1859 for MCM-2 (clone CRCT2.1/D1.9H5) (Serotec Ltd,
Oxford, UK, diluted 1:500 overnight) and (2) MCA 1860 for
MCM-5 (clone CRCT5.1/A2.7A3) (Serotec Ltd, Oxford, UK, diluted
1:200 overnight). For both antibodies, antigen retrieval with
microwaving for 30min, at 750W, in citrate buffer pH 6.0 was
required. The peroxidase-polymer-based method was used with
DAKO Envision kit (DAKO, Carpinteria, CA, USA). Known
positive controls (i.e. a normal tonsil) as well as negative controls
(sections in which anti-MCM-2 and anti-MCM-5 antibodies were
substituted by non-immune mouse serum) were also stained in
each run.
Staining for MCM-2 and MCM-5 was assessed blindly (i.e.
without any knowledge of the clinical data) by two observers. A
difference of greater than 5% between the two assessments was
observed in 7.8% (10/128) and 10.15% (13/128) of cases,
respectively. In these cases, slides were reviewed jointly and a
consensus was reached. Nuclei from about 1000 tumour cells from
systematically randomised fields ( 40) throughout the entire
section were counted and the labelling index (LI) was calculated as
the percentage of labelled nuclei out of the total number of tumour
cells counted. Whenever heterogeneous staining was encountered,
counting was performed in areas of highest density of labelled
cells, identified at medium magnification ( 20), because it has
been proposed that these tumour areas are most likely to be of
biologic significance (Wharton et al, 2001; Rodins et al, 2002). All
clearly identifiable nuclear staining beyond background was
recorded as positive for MCM-2 and MCM-5. No endothelial or
lymphoid cells were included in the counts even though they
expressed MCM-2 and MCM-5.
Cell culture
MDAH-2774 cells were serially passaged as monolayer cultures in
RPMI medium, supplemented with 10% FCS, 1% L-glutamine,
50mgml
 1 streptomycin and 50Uml
 1 penicillin (Gibco-BRL/Life
Technologies, Eggenstein, Germany). The cell-culture flasks (Nunc,
Wiesbaden, Germany) were incubated in a humidified atmosphere
containing 5% carbon dioxide at 371C. Cells grown for the
appropriate time interval were washed with phosphate-buffered
saline (PBS, pH 7.4; 140mM NaCl; 6.5mM Na2HPO4; 2.5mM KCl;
1.5mM KH2PO4) and harvested by a 3-min treatment with 0.25%
trypsin/0.02% EDTA (Gibco-BRL/Life Technologies) in PBS.
Equal amounts of culture medium were added and cells were
centrifuged for 5min at 600g and resuspended in PBS for further
processing.
Cell synchronisation by nocodazole treatment Mitotic arrest was
induced by adding 50ngml
 1 nocodazole (Sigma, Deisen-hofen,
Germany) from a 500mgml
 1 stock solution in dimethyl
sulphoxide (DMSO) to the culture medium and incubating the
cells for 24h, as described previously (Endl and Gerdes, 2000).
After 24h treatment, metaphase cells in G1 were immediately
harvested by gentle shaking and washed two times with PBS.
Immunofluorescence and immunohistochemistry As soon as
synchronised and unsynchronised cells have been harvested, they
were trypsinised, plated (at 1 10
5cellsml
 1) on glass slides in
six-well cell culture plates and fixed by gently removing the culture
medium and adding 2% formaldehyde in PBS (pH adjusted to 7.4)
for 10min on ice. Cells were permeabilised by incubation in 0.25%
Triton X-100 for 5min on ice and washed twice with PBS
containing 4% BSA.
Immediately after this procedure has been completed slides for
immunofluorescence were incubated overnight with Ki-67, MCM-
2, or MCM-5 antibodies at 41C, diluted 1:20 in a humidified
chamber, followed by washing in PBS supplemented with 4% BSA
and incubation with FITC-conjugated anti-mouse secondary
antibody diluted 1:200 (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) for 1h at 41C. For immunohistochemistry, the same
procedure was followed, substituting FITC-conjugated secondary
antibody with DAKO Envision kit, as used for the immuno-
histochemistry of tissue specimens. Ki-67, MCM-2 and MCM-5
Table 2 Clinical data of patients in the validation group with ovarian
adenocarcinomas
Age (years)
Median (range) 58 (22–86)
Histological type
Serous 35 (77.8%)
Mucinous 1 (2.2%)
Endometrioid 3 (6.7%)
Clear cell 3 (6.7%)
Poorly differentiated 1 (2.2%)
Not specified 2 (4.4%)
Histologic grade
1 4 (9.3)
2 20 (46.5)
3 19 (44.2%)
FIGO stage
I 1 (2.2%)
II 6 (13.3%)
III 29 (64.4%)
IV 9 (20.0%)
Primary residual tumour
No 16 (35.6%)
Yes 28 (62.2%)
Not specified 1 (2.2%)
Adjuvant chemotherapy
Platinum-containing 34 (75.6%)
Non platinum-containing 11 (24.4%)
Clinical outcome
Died of ovarian cancer 29 (64.4%)
Alive 16 (35.6%)
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sdilutions in this instance were 1:300, 1:400 and 1:100,
respectively. For both immunohistochemistry and immunofluor-
escence, each experiment was repeated three times. After washing
with PBS, all slides were finally incubated in glycerol and examined
under the microscope. Immunofluorescence slides were photo-
graphed on fluorescent microscope. At least 300 cells were
examined under the microscope at medium and high-power
magnification and the percentage of cells displaying nuclear
immunoreactivity or immunofluorescence for MCMs and Ki-67
was estimated. Images were stored as TIF files.
Statistical analysis
The normality of distributions was tested with the Kolmogorov–
Smirnov test. Associations between MCM-2 or MCM-5 LI and
histologic type, grade, stage and residual disease were assessed
with Mann–Whitney U-test and Kruskal–Wallis analysis of
variance as appropriate. The correlation between MCM-5 protein
and histologic stage when poorly differentiated and unspecified
tumours were excluded from analysis was tested using Kruskal–
Wallis ANOVA using the Bonferroni correction for multiple
comparisons. The interrelations among MCM-2, MCM-5, Ki-67,
p53, p21
WAF1, p27
Kip1 and Rb, in LMP tumours and adenocarci-
nomas, were analysed with Spearman’s rank correlation coeffi-
cient. The Cuzick extension of the Wilcoxon’s rank sum test was
used to examine the trend of MCM-2 and MCM-5 LI in relation
with increasing tumour stage. The difference between MCM-2 or
MCM-5 LI and Ki-67 LI in ovarian adenocarcinomas was examined
with Wilcoxon’s signed rank paired test and in MDAH-2774 with
the null hypothesis.
Survival analysis was restricted to adenocarcinomas, given that
LMP tumours follow a substantially more favourable clinical
course. The prognostic effect of various parameters (i.e. age,
histologic type, grade, FIGO stage, volume of residual disease, type
of chemotherapy, LI, MCM-2 LI and MCM-5 LI on clinical
outcome, i.e. death of disease) was tested by plotting survival
curves according to Kaplan–Meier method and comparing groups
using the log-rank test, as well as by multivariate analysis. Patients
dying of other causes during the follow-up period were treated as
censored data. In univariate analysis, the numerical variables age,
MCM-2 LI and MCM-5 LI, were categorised on the basis of the
median value. In multivariate analysis, we also included Ki-67,
p21
WAF1, p27
Kip1, p53 and pRb expression to examine whether
their presence may influence the prognostic impact of MCM
proteins. To avoid any ‘data-driven’ categorisation, numerical
variables were entered in multivariate analysis as continuous
variables. Given that MCM-2 and MCM-5 were strongly inter-
related, their significance as independent prognosticators was
tested in separate models.
Statistical analysis was performed using the SPSS for Windows
Software (SPSS Inc., Chicago IL, USA). A P-value of less than or
equal to 0.05 was considered indicative of a statistically significant
difference.
RESULTS
MCM-2 and MCM-5 expression in LMP tumours and
ovarian adenocarcinomas
Immunoreactivity for MCM-2 and MCM-5 was seen in all cases
ranging from 1 to 82% (median: 15%) and from 1 to 75% (median:
20%), respectively (Figure 1). The pattern of staining was mostly
nuclear, although a faint cytoplasmic staining was seen in some
cases, which was disregarded during evaluation, conforming with
previously published data (Meng et al, 2001). Minichromosome
maintenance protein-2- and MCM-5-positive cells were randomly
distributed throughout the neoplastic population in 110 and 112
cases, respectively. A statistically significant positive correlation
was established between MCM-2 and MCM-5 protein levels
(Po0.0001).
The median MCM-2 and MCM-5 LIs were significantly higher in
adenocarcinomas (20 and 24%, respectively) compared to LMP
tumours (5 and 6%, respectively) (Mann–Whitney U-test,
Po0.0001 for both associations). When comparisons between
LMP cases and carcinomas were made for serous and mucinous
types separately, statistically significant differences were recorded
for both MCM-2 (Mann–Whitney U-test, Po0.0001 for serous and
P¼0.0070 for mucinous tumours) and MCM-5 protein expression
(Mann–Whitney U-test, Po0.0001 for serous and P¼0.0020 for
mucinous tumours; Table 2). Within the adenocarcinomas only,
MCM-5 (but not MCM-2) protein expression was also related to
the histologic type (Kruskal–Wallis ANOVA, P¼0.0349), the
highest levels of immunoreactivity being recorded in poorly
differentiated and nonspecified categories (Table 3). However,
when poorly differentiated and unspecified cases, which are
regarded as high-grade disease, were removed from analysis, the
relationship failed to reach statistical significance (Kruskal–Wallis
ANOVA, Bonferroni correction, P¼0.0856).
Minichromosome maintenance protein-2 and MCM-5
expression in ovarian adenocarcinomas in relation to
clinicopathologic parameters
The rate of MCM-2 or MCM-5 positivity significantly increased
with increasing tumour grade (1 vs 2 vs 3, Kruskal–Wallis test:
P¼0.0002 and 0.0006, respectively; Table 4) and the presence of
residual disease (Mann–Whitney U-test: P¼0.0010 in both
relationships). A statistically significant positive association
emerged between MCM-2 and MCM-5 LI and advancing tumour
stage (I&II vs III vs IV, Kruskal–Wallis test: P¼0.0062 and 0.0018,
respectively; Table 4). The Cuzick extension of the Wilcoxon’s
rank sum test confirmed the presence of a significant trend of
increasing MCM-2 and MCM-5 expression with increasing tumour
stage (P¼0.0100 and 0.0300, respectively).
Relationship of MCM-2 LI and MCM-5 LI with
proliferation rate
A strong positive correlation was established between MCM-2 or
MCM-5 expression level and Ki-67 LI (Spearman’s rho¼0.7214,
Po0.0001 and rho¼0.6449, Po0.0001, respectively), which
remained after stratification of our cases into borderline
(Po0.0001 and 0.0038, respectively) or carcinoma categories
(P¼0.0242 and o0.0001, respectively). Within both the LMP
and adenocarcinoma groups MCM-5 (but not MCM-2)-positive
cells tended to outnumber Ki-67-positive cells (Wilcoxon’s signed
rank paired test P¼0.0300 and 0.0206, respectively, Figure 2).
Within the adenocarcinomas statistically significant differences
between MCM-5 and Ki-67 levels were recorded only in grade I
tumours (P¼0.0049).
Minichromosome maintenance protein-2, MCM-5 and
Ki-67 expression in MDAH-2774 cells
In asynchronous cell culture, a greater number of cells expressed
MCM-2 and MCM-5 than Ki-67, the corresponding LIs being 95, 98
and 88%, respectively (MCM-2 vs Ki-67 P¼0.0759, MCM-5 vs
Ki-67 P¼0.0056). This difference remained and even became
greater in G1 arrested synchronised cells (MCM-2 vs Ki67
Po0.0001, MCM-5 vs Ki-67 P¼0.0039). The LIs in this instance
were 79, 70 and 50%, respectively, significantly lower than those in
asychronous cell culture (MCM-2 P¼0/0008, MCM-5 Po0.0001,
Ki-67 Po0.0001, Figure 3).
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p27
Kip1, p21
WAF1, p53 and pRb
In LMP tumours, the levels of MCM proteins did not correlate with
either p27
Kip1, pRb, p21
WAF1 or p53 expression (P40.10). Also, in
ovarian carcinomas, no association was established between
p21
WAF1 and MCM-2 or MCM-5 LIs (P40.10). However, higher
MCM-2 or MCM-5 LIs were observed in ovarian adenocarcinomas
with p53 Lis 410% (Kruskal–Wallis ANOVA P¼0.0022 and
0.0300, respectively).
In carcinomas, a statistically significant inverse relation was
observed between MCM-2 and p27
Kip1 levels (Spearman’s
rho¼ 0.3277, P¼0.0068, Figure 4A). Moreover, statistically
significant positive associations emerged between MCM-2 or
MCM-5 LI and p53 expression (Spearman’s rho¼0.3493,
P¼0.0038, Figure 4B and rho¼0.2348, P¼0.0500, Figure 4C,
respectively).
Survival analysis: population group
In univariate analysis, the parameters adversely affecting
survival were high grade (P¼0.0330), advanced stage
(P¼0.0193), the presence of bulk residual disease (P¼0.0001),
increased (X20%) MCM-2 expression (P¼0.0004) and increased
(X25%) MCM-5 expression (P¼0.0100) (Figure 5A and B),
whereas histologic type attained a marginal significance in this
regard (P¼0.0900).
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Figure 1 Immunohistochemical expression of MCM-2 and MCM-5 in ovarian adenocarcinomas. (A) MCM-2 protein expression in many nuclei of a grade
3 endometrioid ovarian adenocarcinoma (original magnification  400). (B) Minichromosome maintenance protein-2 protein expression in a grade 1
ovarian adenocarcinoma: scattered nuclei stained positive (original magnification  400). (C) Minichromosome maintenance protein-5 protein expression in
a grade 3 serous ovarian adenocarcinoma (original magnification  400). (D) Moderate MCM-5 immunopositivity in a grade 2 endometrioid ovarian
adenocarcinoma (original magnification  200). (E) Extensive MCM-2 positivity in a grade 2 serous ovarian adenocarcinoma (original magnification  200).
(F) Diffuse MCM-5 positivity in a grade 3 endometrioid ovarian adenocarcinoma (original magnification  200).
Table 3 MCM-2 and MCM-5 expression in LMP tumours and ovarian
adenocarcinomas
Histology
MCM-2 LI
(%) median (range)
MCM-5 LI
(%) median (range)
LMP tumours, n¼42
Serous 5.5 (1–25) 10 (2–20)
Mucinous 5 (1–15) 5 ( 1–20)
Adenocarcinomas, n¼72
Serous 20 (2–60) 22.5 (7–70)
Mucinous 20 (8–35) 24 (15–70)
Endometrioid 17.5 (8–82) 27.5 (8–80)
Clear cell 15 (2–70) 20 (5–50)
Poorly differentiated/
Not specified
35 (20–50) 40 (10–75)
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survival including MCM-2 LI, stage, grade, histology, chemo-
therapy and the presence of residual disease, MCM-2 protein
expression emerged as an independent predictor of adverse
outcome (P¼0.001) along with advanced stage of the disease
(Table 5, model A1). When multivariate analysis was repeated for
MCM-5 and the aforementioned clinicopathological parameters,
MCM-5 LI emerged as the only independent predictor of survival
(P¼0.0360; Table 5, model B1) When the other cell cycle
regulators were also introduced in the models, MCM-2 remained
an independent predictor of survival (Po0.0001) along with the
stage of the disease and p21
WAF1 expression (Table 5, model A2),
whereas MCM-5 remained the only independent predictor of
survival against all other parameters examined (P¼0.0220; Table 5,
model B2).
Univariate survival analysis: validation group
To detect a difference of 0.5282 between 0.9357 and 0.4093 – the
probability of surviving in high MCM-2 (X20%) and low MCM-2
(o20%) expression group after 60.00 months, as calculated in the
population group – using a two-sided log-rank test and to achieve
90% power at a 0.05 significance level, 42 patients would be
needed. Accordingly, for the detection of a difference of 0.6745
between 0.9524 and 0.2779 – the probability of surviving in high
MCM-5 (X25%) and low MCM-5 (o25%) expression group after
60.00 months, as calculated in the population group – using a two-
sided log-rank test and to achieve 90% power at a 0.05 significance
level 29 patients would be needed. Consequently, we formed a
random independent adequately powered validation group of 45
patients with ovarian carcinoma.
Using the optimal cutoff of 20% for MCM-2 expression and 25%
for MCM-5 expression the 45 patients in the validation group were
stratified into low and high expression group. The overall survival
was significantly lower in the high MCM-2 expressor group when
compared to that in the low MCM-2 expressor group (log-rank
test, Po0.0001). The same applied to patients with high MCM-5
expression ((X25%) compared to those with low MCM-5
expression (log-rank test, Po0.0001)) (Figure 5C and D).
DISCUSSION
In the present study, we have clearly demonstrated the nuclear
localisation of MCM-2 and MCM-5 proteins in ovarian neoplasms.
A faint cytoplasmic immunostaining was also seen in some cases,
but was not taken into accounting statistical analysis, in keeping
with previous observations in urothelial and prostatic carcinomas
(Meng et al, 2001; Korkolopoulou et al, 2005). Studies in the
budding yeast have documented the distribution of MCM-2 and
MCM-3 proteins in both the cytoplasm and nucleus in relatively
constant levels throughout the cell cycle (Tye, 1999). However,
about 5–10% of these proteins were tightly associated with
chromatin from early G1 phase to the beginning of S phase, when
replication initiation occurs (Blow and Laskey, 1988), suggesting
that active MCM complex is likely to be localised to chromatin.
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Figure 2 Scatter plot indicating the difference (A) between MCM-5LI and Ki-67LI and (B) between MCM-2LI and Ki-67LI. It is obvious that in the
majority of cases the difference between MCM-5 and Ki-67 levels is 40.
Table 4 MCM-2 and MCM-5 expression as related to clinicopathologic
variables in ovarian carcinomas
Variable
MCM-2 LI
(%) median (range)
MCM-5 LI
(%) median (range)
Histological grade
1 10 (2–50) 30 (3–70)
2 17.5 (5–45) 20 (5–60)
3 30 (5–82) 42.5 (5–80)
Kruskal–Wallis test P¼0.0002 P¼0.0006
Stage
I–II 15 (2–50) 20 (3–75)
III–IV 20 (5–82) 35 (5–80)
Mann–Whitney U test P¼0.0062 P¼0.0018
Residual tumor
No 15 (2–45) 20 (3–70)
Yes 27.5 (5–82) 35 (10–80)
Mann–Whitney U test P¼0.0030 P¼0.0010
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sYet, nuclear expression and activity are not synonymous terms as
nuclear MCM is entirely unbound in G2 (Tye, 1999).
A statistically significant positive correlation was established
between MCM-2 and MCM-5 protein levels suggesting
the requirement of both proteins to create a functional
complex. In this context, various methods have documented
the physical interactions among members of the MCM family in
man and other organisms (Richter and Knippers, 1997). Thus,
immunoprecipitation of one of the MCM proteins often leads
to the co-precipitation of all six members of the MCM family
(Kubota et al, 1997; Tho ¨mmes et al, 1997). Chromatin immuno-
precipitation in HeLa cells at the G1/S-phase transition indicates
that all six MCMs colocalise on shared DNA fragments of 500
base pairs, advocating that these proteins are bound to chromatin
as a multimeric complex containing all six subunits (Ritzi et al,
1998).
AB
CD
Figure 3 Immunohistochemical expression of MCM-5 and Ki-67 in an ovarian carcinoma cell line: (A) Ki-67 expression in asynchronous cell culture; (B)
MCM-5 expression in asynchronous cell culture; (C) Ki-67 expression in G1 synchronised cell culture; (D) MCM-5 expression in G1 synchronised cell culture
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sGiven that MCMs play a critical role in initiation of DNA
synthesis and DNA replication must precede each cell division,
their expression is expected to correlate with cell proliferation.
Along this line, accumulating evidence highlights the value of
MCM protein expression as a novel indicator of cell proliferation
(Facoetti et al, 2006). Indeed, in our study, strong correlations
emerged between MCM-2 or MCM-5 LIs and the conventional
proliferation index Ki-67, which remained even after stratification
of our cases into borderline or carcinoma categories. Our work in
an ovarian cancer cell line stained immunohistochemically and by
immunofluorescence for MCM-2, MCM-5 and Ki-67 verified that
MCM-positive cells (especially MCM-5) outnumbered Ki-67-
positive cells in unsynchronised cells (98 vs 88%) and that this
difference became even greater in synchronised cells arrested
in G1 (79 vs 55%). However, and in keeping with our previous
observations in muscle-invasive urothelial carcinomas
(Korkolopoulou et al, 2005), median values of MCM-5 were
significantly higher than those of Ki-67 in ovarian carcinomas as
well as in LMP tumours. It has been claimed that MCMs represent
a potentially more accurate means of determining the proliferative
fraction within a tumour than the conventional proliferation
indices probably because the latter fail to label cells in early G1
(Osaki et al, 2002; Korkolopoulou et al, 2005; Schrader et al, 2005).
However, the discrepancy between MCMLIs and Ki-67 LI might be
a reflection of the fact that Ki-67 is downregulated early in the
differentiation programme, whereas MCMs are downregulated
later, when the cells adopt a terminally differentiated phenotype
(Eward et al, 2004; Kingsbury et al, 2005). Thus, the ‘improved’
sensitivity of MCMs as markers of proliferating cells could reside
in the identification of differentiating cells, which is consistent
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Figure 5 Kaplan–Meier curves of overall survival according to MCM-5 and MCM-2 protein expression in both the population group (A, B) and the
validation group (C, D).
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swith our finding that the highest difference among MCM-5 and
Ki-67 is recorded within the grade I (i.e. the well-differentiated)
tumours. Therefore, the higher growth fraction identified by
MCMs appears to arise either from the fact that MCMs identify all
cell cycle phases, as opposed to the low expression of Ki-67 in early
G1 and M phase, or from the different kinetics of MCMs and Ki-67
downregulation during exit form the mitotic cycle into the
differentiated state.
As mentioned above, during early G1, the MCM loading factors
Cdc6 and Cdt1 recruit the MCM proteins to chromatin near origins
of replication where they remain assembled until late G1 phase. S
phase is then triggered by high cyclin A/CdK2 and Dbf4/Cdc7
levels that activate the complex of MCM proteins and chromatin
(Tachibana et al., 2005). On the other hand, in most normal
tissues, p27
Kip1 negatively regulates cell proliferation by inhibiting
CdKs (Schmider-Ross et al, 2006). Thus, the demonstration in this
study of an inverse correlation between p27
Kip1 and MCM-2 is in
alignment with the underlying mechanism of regulation of cell
proliferation.
Although p21
WAF1 also constitutes a CdK inhibitor, no
association was established between p21
WAF1 and MCM-2 or
MCM-5 LIs. However, the inhibitory function of p21
WAF1 on DNA
synthesis requires the formation of quarternary complexes
composed of cyclins, CdKs and PCNA and is thought to be
stoichiometrically regulated being exerted only when p21
WAF1 is in
molar excess (reviewed by Vassilopoulos et al, 2003). If the ratio of
p21
WAF1 to CdK is less than one, p21
WAF1 serves only as an
assembling factor for CdK complex and does not inhibit CdK
activity.
In LMP tumours, the levels of MCM proteins did not correlate
with either p27
Kip1 or p21
WAF1 in keeping with our previous
observations concerning Ki-67, p21
WAF1 and p27
Kip1 expression in
LMP ovarian tumours (Korkolopoulou et al, 2002, Vassilopoulos
et al, 2003). Palazzo et al (2000) noted a similar lack of correlation
between proliferation rate and the levels of p21
WAF1 in LMP
tumours. The authors claimed that this finding was to be expected
in tumours with a low proliferation index as well as in normal
tissues and benign tumours. The low Ki-67 levels in LMP tumours
might indicate that most cells are still able to exit from the cell
cycle into G0, as opposed to malignant tumours. Following this line
of argument, this group of authors (Palazzo et al, 2000) attributed
the lack of p21
WAF1 in non-cycling cells to degradation of the
protein, once the cell has entered a cell cycle exit state.
Given that p53 immunoreactivity in most carcinomas has been
regarded as a surrogate marker for, although not a proof of, gene
mutation or inactivation, the observed correlations between
MCM-2 or MCM-5 on one hand and p53 on the other hand might
be indicative of the positive effect exerted by mutant-type p53 on
cell cycle progression. This concept is reinforced by the fact that
higher MCM-2 and MCM-5 LIs were observed in the 32 (47.8% of
cases) ovarian adenocarcinomas with p53 LI more than 10%, a
cutoff that that has been shown to be efficient for the identification
of p53 mutations in paraffin blocks staining (Banks et al, 1986).
According to a recent study, p53 mutation prevalence estimates
were 45, 5 and 1%, respectively, for invasive, LMP and benign
ovarian tumours (Reles et al, 2001; Kmet et al, 2003). As opposed
to carcinomas, no relation was established between p53 and cell
proliferation markers in LMP tumours.
Minichromosome maintenance protein-2 and MCM-5 proteins
demonstrated increased expression in ovarian adenocarcinomas as
opposed to LMP tumours. These differences remained significant
when serous and mucinous neoplasms were investigated sepa-
rately. Moreover, no difference existed in MCMs expression
between serous and mucinous LMP tumours, whereas in
adenocarcinomas, a higher level of MCM-5 expression was
observed in poorly differentiated category as compared with the
remaining histologic types. However, the fact that this correlation
did not retain its statistical significance when the poorly
differentiated category was removed from analysis could possibly
reflect the significant correlation between histologic grade and
MCM-5 protein, as poorly differentiated tumours are regarded as
high-grade disease. Our findings support and expand the
previously reported increase of MCM-2 expression during the
progression from normal ovary through serous cystadenoma and
serous borderline tumours to serous cystadenocarcinomas (Scott
et al, 2004). Consistent with these findings, MCM genes have also
been found to be upregulated at the mRNA level in a range of
malignancies by expression microarray analysis (Rosenwald et al,
2003; Neben et al, 2004; Yu et al, 2004b). No particular MCM
protein appears to be upregulated in isolation, which is consistent
with their function as a heterohexameric complex (Tachibana et al,
2005).
In ovarian adenocarcinomas, MCM-2 and MCM-5 expression
increased with increasing tumour grade, advancing stage and the
presence of bulk residual disease. Significant associations between
MCM overexpression and high grade have also been described in
prostate (Meng et al, 2001), urothelial (Korkolopoulou et al, 2005)
and renal carcinomas (Rodins et al, 2002) as well as in
oligodendrogliomas (Wharton et al, 2001). Moreover, in vitro
studies have clearly shown a dramatic decrease in the levels of
MCM-2 mRNA as well as of MCM-3 protein during the
differentiation of human myeloblast HL60 cells (Philipova et al,
Table 5 Cox proportional hazard estimation of overall survival in ovarian adenocarcinomas
95% confidence limits for the hazard ratio
Covariate P Hazard ratio Lower Upper
A1
a
MCM-2 0.001 1.058 1.023 1.093
Stage (I/II vs III/IV) 0.045 11.16 1.06 117.52
B1
b
MCM-5 0.036 1.027 1.001 1.053
A2
c
MCM-2 o0.0001 1.116 1.049 1.187
p21
WAF1 0.028 0.621 0.406 0.949
B2
d
MCM-5 0.022 1.043 1.006 1.082
aA1 model included the conventional clinicopathologic parameters and MCM-2LI.
bB1 model included the conventional clinicopathologic parameters and MCM-5LI.
cA2 model
included the conventional clinicopathologic parameters, MCM-2LI, Ki-67LI and the cell cycle regulators.
dB2 model included the conventional clinicopathologic parameters, MCM-
5LI, Ki-67LI and the cell cycle regulators.
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s1991; Musahl et al, 1998), respectively, which support our findings.
Relevant to this issue is the observation that overexpression of
p21
WAF1 or p27
Kip1 in the promyelocytic leukemia cell line
accelerates its lineage-specific differentiation (Wang et al, 1998;
Zhou et al, 1999).
A main scope of our study was to investigate for the first time
the prognostic relevance of MCM-2 and MCM-5 expression in
ovarian adenocarcinomas. In both univariate and multivariate
survival analysis, overexpression of each protein associated
significantly with poor overall patients’ survival. More impor-
tantly, the results of univariate survival analysis were validated in
an independent set of patients, using the same cutoff points of
MCM expression as in the population study. The confirmation of
the adverse prognostic effects of a notorious group of universally
established prognostic factors (grade, stage, residual disease)
proves that our cohort was quite representative and that survival
analysis was valid.
Immunohistochemical studies and expression microarray ana-
lyses have independently identified MCM proteins as powerful
indicators of worse clinical outcome in various tumour types
(Meng et al, 2001; Ramnath et al, 2001; Wharton et al, 2001; Hunt
et al, 2002; Rodins et al, 2002; van ‘t Veer et al, 2002; Gonzalez
et al, 2003; Kato et al, 2003; Kodani et al, 2003; Kruger et al, 2003;
Rosenwald et al, 2003; Sotiriou et al, 2003; Hashimoto et al, 2004;
Neben et al, 2004; Yu et al, 2004a; Korkolopoulou et al, 2005;
Shetty et al, 2005). The MCM genes have also appeared as part of
‘poor’ prognostic signatures in breast cancer (van ‘t Veer et al,
2002; Sotiriou et al, 2003; Yu et al, 2004a), mantle cell lymphoma
(Rosenwald et al, 2003) and medulloblastoma (Neben et al, 2004),
whereas in cervical cancer, MCM protein expression appears
promising as a predictor of response to radiation therapy
(Mukherjee et al, 2001).
In conclusion, in the present study, we have investigated for the
first time MCM-2 and MCM-5 expression in LMP tumours and
ovarian adenocarcinomas in relation with clinicopathologic
parameters, cell cycle modulators and patients’ survival. Both
proteins associated significantly with high grade, advanced stage
and residual disease as well as with Ki-67 proliferative index.
MCM-2 LI was inversely related to CdK inhibitor p27
Kip1, whereas
both MCM-proteins correlated positively with p53 expression in
carcinomas. MCM-2 and MCM-5, but not Ki-67, emerged as
independent predictors of poor overall survival, implying that
these molecules may be used to refine the prognostic information
conveyed by standard predictors of outcome. On the basis of
these findings, the tempting possibility of targeting replication
proteins and their regulators as part of antitumour therapies
that interfere with cancer cell proliferation certainly merits
consideration.
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